Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1992-03-02
1994-09-20
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 530351, 514 21, 514885, 514889, 514400, 5483355, A61K 4505, C07K 300
Patent
active
053487397
ABSTRACT:
A method of inhibiting the development of malignant tumors and the formation of metastases of malignant tumor cells in a subject carrying the comprises administering to the subject IL-2 and an agent selected from the group consisting of histamine, a histamine structural analogs having H.sub.2 -receptor activities, an endogenous histamine releasing preparation, and a non-histamine derivative H.sub.2 -receptor agonist; the agent and the IL-2 being administered in amounts and for a time effective to attain the desired effect. A method of increasing the anti-tumor cell effect of IL-2 in a subject comprises co-administering to the subject IL-2 and an agent such as histamine, histamine structural analogs having H.sub.2 -receptor activities, endogenous histamine releasing preparations or H.sub.2 -receptor agonists, the agent and the IL-2 being administered in anti-tumor effective amounts and for a period of time effective to attain the desired effect.
REFERENCES:
Osband et al, The Lancet vol. 1, No. 8221, pp. 636-638, Mar. 21, 1981.
Burtin et al, Cancer Letters, vol. 12, No. 3, pp. 195-201, Apr. 1981.
Lotze et al, Interleukin 2, ed. K. A. Smith, Academic Press Inc., San Diego, Calif., pp. 237-245, 1988.
Rosenberg, Annals of Surgery, vol. 208, No. 2, pp. 121-135, Aug. 1988.
Philips, et al. J. Exp. Med., vol. 170, pp. 291-296 (1989).
Schleimer, et al. J. Immunol., vol. 143, pp. 1310-1317 (Aug. 1989).
Alam, et al. J. Immunol., vol. 142, No. 10, pp. 3431-3435 (1989).
Richtsmeier, et al. Anol. Otol. Rhinol. Laryngol., vol. 96, No. 5, pp. 569-572 (1987).
Dohlsten, et al. Cellular Immunol., vol. 101, No. 2, pp. 493-501 (1986).
Nair, M. P. N. et al., J. Immunol. 136:2456 (1986).
Dempsey, R. A. et al., J. Immunol. 129:2504 (1982).
Segerson, T. P. et al. Science 238:75 (1987).
Hellstrand, K., et al., Int. Archs. Allergy Appl. Immun. 84:247-255 (1987).
Smith, K. A. Science 240:1169 (1988).
Rosenberg, S., Ann. Surgery 108:111 (1988).
Hanna, N. Biochim. Biophys. Acta 780:213 (1985).
Beer, D. J. et al., Adv. Immunol. 35:209 (1984).
Barna, B. P. et al., Oncology 40:43 (1983).
Lespinats, G. et al., Br. J. Cancer 50:545 (1984).
Nordlund J. J. et al., J. Invest. Dermatol 81:28 (1983).
Droege, W. et al., Chem Abstracts, vol. 104, No. 17, Apr. 28, 1986, Abstract 146898m.
Okamoto, H., "Possible Involvement of Adenosine 3'-5'-Cyclic Monophosphate . . . " Immunology, 70:186-190 (1990).
Hellstrand, "Histamine H.sub.2 -Receptor Mediating Regulation of Human Natural Killer Cell Activity," J. Immunol, vol. 137, No. 2, pp. 656-660, Jul. 15, 1986.
Hellstrand, "Enhancement of Human NKCC by Serotonin," Cellular Immunol., vol. 127, pp. 199-214 (1990).
Hellstrand, "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," J. Immunol., vol. 139, No. 2 pp. 869-875, published Aug. 1, 1987.
Hellstrand, "Monocyte Induced Down-Modulation of CD16 and CD56 Antigens on Human NK Cells and Its Regulation by Histamine H.sub.2 -Receptors," Cellular Immunol., vol. 138, pp. 44-54 (1991).
Dillman, et al., "Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial," J. National Cancer Institute, 82(16):1345-1348, Aug. 15, 1990.
Hellstrand, "Cell-to-Cell Mediating Inhibition of NK Cell Proliferation by Monocytes and its Regulation by Histamine H.sub.2 -Receptors," Scand. J. Immunol., vol. 34, pp. 741-752 (1991).
Hellstrand, "Synergistic Activation of Human NKCC by Histamine and IL-2," Int. Arch. Allergy Appl. Immunol., vol. 92, pp. 379-389 (1990).
Hellstrand, "Role of Histamine in NK Cell-Mediated Resistance Against Tumor Cells," J. Immunol., vol. 145, No. 12, pp. 4365-4370, Dec. 15, 1990.
Hellstrand, et al., "Interleukin-2 Can Induce Suppression of Human Natural Killer Cell Cytotoxicity," Clin. Exp. Immunol., 77(3):410-416 (1989).
Hellstrand, "Monocyte Mediated Suppression of IL-2 Induced NK Cell Activation," Scand. J. Immunol., vol. 32, No. 2, pp. 183-192 (1990).
Hellstrand, "A Cell-to-Cell Mediated Interaction Involving Monocytes and Non-T/CD16=NK Cells is Required for Histamine H.sub.2 -Receptor Medicated NK Cell Activation," Scand. J. Immunol., vol. 31, pp. 631-644 (1990).
Hellstrand, BiogenicAmines in the Regulation of Human Natural Killer Cell Cytotoxicity (Thesis), Medi Press, Goteborg, Sweden, 1987.
Smith, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy," Comprehensive Therapy, 16(1):8-13 (1990).
Schantz, et al., "A Phase II Study of Interleukin-2 and Interferon-Alpha in Head and Neck Cancer," Investigation New Drugs, 10:217-223 (1992).
Mavligit, et al., "Splenic Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases," J. Clin. Oncol., 8(2):319-324 (Feb. 1990).
Krigel, et al., "Renal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon," J. Clin. Oncol., 8(3):460-467 (Mar. 1990).
Dutcher, et al., "A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients with Metastic Melanoma," J. Clin. Oncol., 9(4):641-648 (Apr. 1991).
Dillman, et al., "Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer; A National Biotherapy Study Group Trial," J. Clin. Oncol., 9(7):1233-1240 (Jul. 1991).
Stoter, et al., "Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastic Melanoma: A Multicenter Phase II Study," J. Clin. Oncol., 9(9):1687-1691 (Sep. 1991).
Weiss, et al., "A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus Lymphokine-Activated Killer Cells for Advanced Renal cell Carcinoma," J. Clin. Oncol., 10(2):275-281 (Feb. 1992).
Abrams, et al., "High-Dose Recombinant Interleukin-2 Alone: A Regimen with Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," J. National Cancer Institute, 82(14):1202-1206 Jul. 18, 1990.
Hellstrand, "Serotonergic 5-HT1A Receptors Regulate a Cell Contact Mediated Interaction Between NK Cells and Monocytes," Scand. J. Immunol., vol. 37, pp. 7-18, published 1993.
Mertens, et al., "Sustained Indomethacin and Ranitidine with Intermittent continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A Phase II Study," J. Clinical Oncology, 5(2):107-113 (1993).
Mertens, et al., "Effect of Indomethacin Plus Ranitidine in Advanced Melanoma Patients on High-Dose Interleukin-2," Lancet, 340:397-398, Aug. 15, 1992.
Saarloos, et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stemk Cells," Cancer Research, 52:6452-6462, Dec. 1, 1992.
Saarloos, et al., "Effects of Histamine Type-2 Receptor Antagonists on Indomethacin and IL-2 Immunotherapy of Metastasis," Clin. Exp. Metastasis, 11(3):275-283 (1993).
Khoo, et al., "Immunotherapy of Mammary Adenocarcinoma Metastases in C3H/HeN Mice with Chronic Administration of Cyclo-Oxygenase Inhibitors Alone or in Combination with IL-2," Clin. Exp. Metastasis, 10(4):239-252 (1992).
Sleijfer, et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," J. Clin. Oncol., 10(7):1119-1123 (Jul. 1992).
Ilson, et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients with Advanced Renal Cell Carcinoma," J. Clin. Oncol., 10(7):1124-1130 (Jul. 1992).
Thompson, et al., "Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma," J. Clin. Oncol., 10(6):960-968 (Jun. 1992).
Budd, et al., "Phase I Trial of High-Dose Bolus Interleukin-2 and Interferon Alfa-2a in Patients With Metastatic Malignancy," J. Clin. Oncol., 10(5):804-809 (May 1992).
Hallstrand, "Regulation of the NK Cell Response to IFN-.alpha.by Biogenic Amines" J. Interferon Rsch., vol. 12, pp. 199-206 (1992).
Hellstrand Jan U. K.
Hermodsson Svante H.
Mohamed Abdel A.
Suntello, Inc.
Wityshyn Michael G.
LandOfFree
Combined anti-tumor therapy with interleukin-2 and histamine, an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined anti-tumor therapy with interleukin-2 and histamine, an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined anti-tumor therapy with interleukin-2 and histamine, an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2429671